Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Poland
Management Report
Published: January 2010
Pages: 50
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
POLAND - MARKET REVIEW
Poland has the second largest economy in Central & Eastern Europe, although in per capita terms it is around average. Poland was the only EU country that did not see its economy contract in 2009 as a result of the economic crises. This was due to a fairly low dependency on loans, high consumer spending and the fact that exports account for only 30% of GDP. Poland is also the largest beneficiary of EU funds among the 27 member states, receiving around 20% of the EU's total financial support under the cohesion policy. The large population of 38.1 million keeps the demand for pharmaceuticals high. However, the overall population size is slowly decreasing whilst the population aged 65 years and over is rising. This age group is expected to represent 15.4% of the total by 2015, up from 13.0% in 2010, placing increased pressure on the health system.
Debate continues over the adequacy of reimbursement and data exclusivity provisions. PhRMA has taken issue with Poland’s failure to fully implement EU legislation regarding data exclusivity. Poland extended its data exclusivity period to six years when it joined the EU; the standard EU ten-year term only applies to drugs registered through the European procedures. In addition, the procedure relating to the reimbursement of drugs is unclear and manufacturers often argue with the MoH over the criteria used for deciding whether or not a drug should be included on the refund list. It is claimed that individual reviews of applications rarely take place and the results are rarely communicated back to the producer. Time scales are also barely adhered to. Decisions should be made within 180 days, but they usually take over a year. Poland is yet to implement the transparency directive 89/105/EEC, which identifies time frames and general rules for pricing and reimbursement decisions.
In 2004, the European Generic Medicines Association estimated that generics represented 65.2% of the market in terms of value and 86.5% in terms of volume. Domestic manufacturers choose to produce generics as there is a shortage of funding for R&D. Also, cheap locally-produced generics tend to be placed on the reimbursement list rather than branded drugs, in order to keep costs down. Whilst there are only two original Polish medicines currently on the market (Vratizolin and Davercin), research into innovative drugs is taking place, namely by the Pharmaceutical Research Institute in Warsaw and some local companies such as Adamed. The potential for R&D expansion in Poland is great, as scientists are well-educated and creative.
In 2010, the Polish market for pharmaceuticals is twice that of Hungary; in per capita terms, the market is similar to Croatia. Imports supply around 66% of the market in value terms. The Polish pharmaceutical market is predicted to expand at a CAGR of 7.2% in US dollar terms over the next few years, driven by a relatively strong economy, import growth and the ageing population. The demand is currently for modern, innovative drugs, which are seldom developed by local manufacturers as most domestic producers do not have the resources to fund research into new molecules. Until local investments in R&D grow, overseas manufacturers have the opportunity to cover the areas that are currently overlooked.
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
POLAND - MARKET REVIEW
Poland has the second largest economy in Central & Eastern Europe, although in per capita terms it is around average. Poland was the only EU country that did not see its economy contract in 2009 as a result of the economic crises. This was due to a fairly low dependency on loans, high consumer spending and the fact that exports account for only 30% of GDP. Poland is also the largest beneficiary of EU funds among the 27 member states, receiving around 20% of the EU's total financial support under the cohesion policy. The large population of 38.1 million keeps the demand for pharmaceuticals high. However, the overall population size is slowly decreasing whilst the population aged 65 years and over is rising. This age group is expected to represent 15.4% of the total by 2015, up from 13.0% in 2010, placing increased pressure on the health system.
Debate continues over the adequacy of reimbursement and data exclusivity provisions. PhRMA has taken issue with Poland’s failure to fully implement EU legislation regarding data exclusivity. Poland extended its data exclusivity period to six years when it joined the EU; the standard EU ten-year term only applies to drugs registered through the European procedures. In addition, the procedure relating to the reimbursement of drugs is unclear and manufacturers often argue with the MoH over the criteria used for deciding whether or not a drug should be included on the refund list. It is claimed that individual reviews of applications rarely take place and the results are rarely communicated back to the producer. Time scales are also barely adhered to. Decisions should be made within 180 days, but they usually take over a year. Poland is yet to implement the transparency directive 89/105/EEC, which identifies time frames and general rules for pricing and reimbursement decisions.
In 2004, the European Generic Medicines Association estimated that generics represented 65.2% of the market in terms of value and 86.5% in terms of volume. Domestic manufacturers choose to produce generics as there is a shortage of funding for R&D. Also, cheap locally-produced generics tend to be placed on the reimbursement list rather than branded drugs, in order to keep costs down. Whilst there are only two original Polish medicines currently on the market (Vratizolin and Davercin), research into innovative drugs is taking place, namely by the Pharmaceutical Research Institute in Warsaw and some local companies such as Adamed. The potential for R&D expansion in Poland is great, as scientists are well-educated and creative.
In 2010, the Polish market for pharmaceuticals is twice that of Hungary; in per capita terms, the market is similar to Croatia. Imports supply around 66% of the market in value terms. The Polish pharmaceutical market is predicted to expand at a CAGR of 7.2% in US dollar terms over the next few years, driven by a relatively strong economy, import growth and the ageing population. The demand is currently for modern, innovative drugs, which are seldom developed by local manufacturers as most domestic producers do not have the resources to fund research into new molecules. Until local investments in R&D grow, overseas manufacturers have the opportunity to cover the areas that are currently overlooked.
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES